Carlos Arce‐Lara

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiotherapy for Stage III Non–Small-Cell Lung Cancer: An Analysis of Veterans Health Administration Data

Rafael Santana-Dávila, Kiran Devisetty, Anikó Szabó et al. · Journal of Clinical Oncology · 2014 · 128 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Cisplatin versus Carboplatin-Based Regimens for the Treatment of Patients with Metastatic Lung Cancer. An Analysis of Veterans Health Administration Data

Rafael Santana-Dávila, Anikó Szabó, Carlos Arce‐Lara et al. · Journal of Thoracic Oncology · 2014 · 53 citations · Full text

Medicine, Oncology, Pharmacology +11

Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial

Richard F. Ambinder, Juan Wu, Brent R. Logan et al. · Biology of Blood and Marrow Transplantation · 2019 · 41 citations · Full text

Medicine, Hematology, Immunology +17

A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

Parameswaran Hari, Omar S. Aljitawi, Carlos Arce‐Lara et al. · Biology of Blood and Marrow Transplantation · 2015 · 32 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13